Phases and Mechanisms of Embryonic Cardiomyocyte Proliferation and Ventricular Wall Morphogenesis
- PMID: 31342113
- PMCID: PMC6786952
- DOI: 10.1007/s00246-019-02164-6
Phases and Mechanisms of Embryonic Cardiomyocyte Proliferation and Ventricular Wall Morphogenesis
Erratum in
-
Correction to: Phases and Mechanisms of Embryonic Cardiomyocyte Proliferation and Ventricular Wall Morphogenesis.Pediatr Cardiol. 2020 Jan;41(1):220. doi: 10.1007/s00246-019-02232-x. Pediatr Cardiol. 2020. PMID: 31680222
Abstract
If viewed as a movie, heart morphogenesis appears to unfold in a continuous and seamless manner. At the mechanistic level, however, a series of discreet and separable processes sequentially underlie heart development. This is evident in examining the expansion of the ventricular wall, which accounts for most of the contractile force of each heartbeat. Ventricular wall expansion is driven by cardiomyocyte proliferation coupled with a morphogenetic program that causes wall thickening rather than lengthening. Although most studies of these processes have focused on heart-intrinsic processes, it is increasingly clear that extracardiac events influence or even direct heart morphogenesis. In this review, we specifically consider mechanisms responsible for coordinating cardiomyocyte proliferation and ventricular wall expansion in mammalian development, relying primarily on studies from mouse development where a wealth of molecular and genetic data have been accumulated.
Keywords: Cardiomyocyte proliferation; Congenital heart defects; Epicardium; IGF2; Placenta–heart.
Conflict of interest statement
Compliance with Ethical Standards
Conflict of interest: All authors declare that he/she have no conflicts of interest.
References
-
- Adams RH, Porras A, Alonso G, Jones M, Vintersten K, Panelli S, Valladares A, Perez L, Klein R, Nebreda AR, 2000. Essential role of p38alpha MAP kinase in placental but not embryonic cardiovascular development. Mol Cell 6, 109–116. - PubMed
-
- Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, Evans RM, 1999. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 4, 585–595. - PubMed
-
- Berthet C, Klarmann KD, Hilton MB, Suh HC, Keller JR, Kiyokawa H, Kaldis P, 2006. Combined loss of Cdk2 and Cdk4 results in embryonic lethality and Rb hypophosphorylation. Dev Cell 10, 563–573. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
